Post-polypectomy surveillance colonoscopy: Comparison of the updated guidelines.


Journal

United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807

Informations de publication

Date de publication:
07 2021
Historique:
received: 09 01 2021
accepted: 24 02 2021
pubmed: 3 6 2021
medline: 28 1 2022
entrez: 2 6 2021
Statut: ppublish

Résumé

Recently, three updated guidelines for post-polypectomy colonoscopy surveillance (PPCS) have been published. These guidelines are based on a comprehensive summary of the literature, while some recommendations are similar, different surveillance intervals are recommended after detection of specific types of polyps. In this review, we aimed to compare and contrast these recommendations. The updated guidelines for PPCS were reviewed and the recommendations were compared. For patients with 1-4 adenomas <10 mm with low-grade dysplasia, irrespective of villous components, or 1-4 serrated polyps <10 mm without dysplasia, the European Society of Gastrointestinal Endoscopy (ESGE) and British Society of Gastroenterology (BSG), the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and Public Health England (PHE) (BSG/ACPGBI/PHE) guidelines do not recommend colonoscopic surveillance and instead recommend that the participate in routine CRC screening program (typically based on the fecal immunochemical test), while the USMSTF recommends surveillance colonoscopies 7-10 years after diagnosis of 1-2 tubular adenomas <10 mm and 3-5 years for 3-4 tubular adenomas of the same size. The USMSTF define adenomas with tubulovillous or villous histology as high-risk adenomas; thus, surveillance colonoscopy is recommended after 3 years. However, the ESGE and BSG do not consider such histology as a criterion for repeating colonoscopy at this short interval. For patients with 1-2 sessile serrated polyps (SSPs) <10 mm and those with 3-4 SSPs <10 mm, the USMSTF recommends surveillance colonosocopy after 5-10 and 3-5 years, respectively.

Sections du résumé

BACKGROUND
Recently, three updated guidelines for post-polypectomy colonoscopy surveillance (PPCS) have been published. These guidelines are based on a comprehensive summary of the literature, while some recommendations are similar, different surveillance intervals are recommended after detection of specific types of polyps.
AIM
In this review, we aimed to compare and contrast these recommendations.
METHODS
The updated guidelines for PPCS were reviewed and the recommendations were compared.
RESULTS
For patients with 1-4 adenomas <10 mm with low-grade dysplasia, irrespective of villous components, or 1-4 serrated polyps <10 mm without dysplasia, the European Society of Gastrointestinal Endoscopy (ESGE) and British Society of Gastroenterology (BSG), the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and Public Health England (PHE) (BSG/ACPGBI/PHE) guidelines do not recommend colonoscopic surveillance and instead recommend that the participate in routine CRC screening program (typically based on the fecal immunochemical test), while the USMSTF recommends surveillance colonoscopies 7-10 years after diagnosis of 1-2 tubular adenomas <10 mm and 3-5 years for 3-4 tubular adenomas of the same size. The USMSTF define adenomas with tubulovillous or villous histology as high-risk adenomas; thus, surveillance colonoscopy is recommended after 3 years. However, the ESGE and BSG do not consider such histology as a criterion for repeating colonoscopy at this short interval. For patients with 1-2 sessile serrated polyps (SSPs) <10 mm and those with 3-4 SSPs <10 mm, the USMSTF recommends surveillance colonosocopy after 5-10 and 3-5 years, respectively.

Identifiants

pubmed: 34077635
doi: 10.1002/ueg2.12106
pmc: PMC8280808
doi:

Types de publication

Comparative Study Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

681-687

Informations de copyright

© 2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC. on behalf of United European Gastroenterology.

Références

Am J Surg Pathol. 2013 Mar;37(3):427-33
pubmed: 23348206
Gastroenterology. 2020 Mar;158(4):884-894.e5
pubmed: 31589872
Endoscopy. 2019 Jul;51(7):673-683
pubmed: 30909308
Clin Transl Gastroenterol. 2014 Dec 04;5:e64
pubmed: 25472702
Lancet Oncol. 2017 Jun;18(6):823-834
pubmed: 28457708
Gastroenterology. 2013 Jun;144(7):1410-8
pubmed: 23499951
Dis Colon Rectum. 2017 Sep;60(9):987-991
pubmed: 28796738
Endoscopy. 2020 Aug;52(8):687-700
pubmed: 32572858
Histopathology. 2012 Jul;61(1):47-52
pubmed: 22486166
Gut. 2017 Mar;66(3):446-453
pubmed: 26658145
Gut Liver. 2018 Jul 15;12(4):426-432
pubmed: 29429156
N Engl J Med. 2012 Feb 23;366(8):687-96
pubmed: 22356322
Gastroenterology. 2020 Mar;158(4):1131-1153.e5
pubmed: 32044092
BMJ. 1999 Feb 20;318(7182):527-30
pubmed: 10024268
United European Gastroenterol J. 2021 Jul;9(6):681-687
pubmed: 34077635
Clin Gastroenterol Hepatol. 2009 Jul;7(7):770-5; quiz 711
pubmed: 19268269
JAMA. 2018 May 15;319(19):2021-2031
pubmed: 29800214
N Engl J Med. 2014 Aug 28;371(9):799-807
pubmed: 25162886
Int J Colorectal Dis. 2020 Jul;35(7):1343-1346
pubmed: 32152670
Kobe J Med Sci. 2011 Feb 02;56(5):E204-13
pubmed: 21937868
Gut. 2012 Aug;61(8):1180-6
pubmed: 22110052
Gastroenterology. 2020 Mar;158(4):875-883.e5
pubmed: 31563625
Gut. 2020 Feb;69(2):201-223
pubmed: 31776230
Gastrointest Endosc. 2006 Oct;64(4):614-26
pubmed: 16996358
Endoscopy. 2011 Jul;43(7):560-72
pubmed: 21437854

Auteurs

Naim Abu-Freha (N)

The Institute of Gastroenterology and Hepatology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Lior H Katz (LH)

Department of Gastroenterology and Hepatology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.

Revital Kariv (R)

Department of Gastroenterology and Hepatology, Sourasky Medical Center, and Tel Aviv University, Tel Aviv, Israel.

Elez Vainer (E)

Department of Gastroenterology and Hepatology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.

Ido Laish (I)

Department of Gastroenterology, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Nathan Gluck (N)

Department of Gastroenterology and Hepatology, Sourasky Medical Center, and Tel Aviv University, Tel Aviv, Israel.

Elizabeth E Half (EE)

Department of Gastroenterology, Rambam Health Care Campus, The Rappaport Faculty of Medicine, Technion, Haifa, Israel.

Zohar Levi (Z)

Department of Gastroenterology, Beilinson Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH